<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01597414</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-75111-10114</org_study_id>
    <secondary_id>2011-006342-32</secondary_id>
    <nct_id>NCT01597414</nct_id>
  </id_info>
  <brief_title>Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1</brief_title>
  <official_title>Pertuzumab + Trastuzumab (PH) Versus PH Plus Metronomic Chemotherapy (PHM) in the Elderly HER2+ Metastatic Breast Cancer Population Who May Continue on T-DM1 Alone Following Disease Progression While on PH / PHM: an Open-label Multicentre Randomized Phase II Selection Trial of the EORTC Elderly Task Force and Breast Cancer Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy and HER2 targeted agents can improve survival significantly in metastatic breast
      cancer. Chemotherapy however is associated with significant side-effects and can impact on
      Quality of Life and functionality in older patients.

      The investigators aim to establish HER2 targeted regimens with minimal toxicity in order to
      delay or even avoid the use of classical chemotherapy because of competing risks of death in
      this frail/elderly patient group.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival rate</measure>
    <time_frame>6 months after patients in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer specific survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate as measured by RECIST v1.1</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of HRQoL as assessed by EORTC QLQ-C30 and ELD 14</measure>
    <time_frame>Up to 1 year after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of geriatric assessment</measure>
    <time_frame>Up to 1 year after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>if T-DM1: progression free survival rate</measure>
    <time_frame>6 months after start of T-DM1 treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Elderly Metastatic Breast Cancer Population</condition>
  <arm_group>
    <arm_group_label>Pertuzumab + trastuzumab (PH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pertuzumab + trastuzumab. After progression,patients will be given the option of receiving T-DM1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PH + metronomic chemotherapy (PHM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pertuzumab + trastuzumab + metronomic chemotherapy. After progression,patients will be given the option of receiving T-DM1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab + trastuzumab</intervention_name>
    <description>Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.
Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.
if T-DM1: 3.6 mg/kg IV, every 3 weeks.</description>
    <arm_group_label>Pertuzumab + trastuzumab (PH)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab + trastuzumab + metronomic chemotherapy</intervention_name>
    <description>Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A</description>
    <arm_group_label>PH + metronomic chemotherapy (PHM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven HER-2 positive

          -  Newly diagnosed or recurrent (after surgery) stage IV disease (TNM/AJCC v.7).

          -  Patients must have measurable (RECIST v. 1.1) or evaluable disease

          -  Performance status (PS) 0-3 (WHO)

          -  Age ≥ 70 years of age, or ≥ 60 years old with required number of dependencies

          -  Life expectancy of more than 12 weeks

          -  Previous adjuvant chemotherapy/anti HER-2 therapy after surgery is allowed, given that
             the time interval from end of previous treatment to initiation of treatment for
             metastatic disease is ≥ 6 months.

          -  Up to one line of anti-HER therapy (trastuzumab or lapatinib) is allowed in
             combination with hormone therapy for hormone sensitive metastatic breast cancer.

          -  Adequate organ function

          -  Before patient randomization, written informed consent must be given according to
             ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          -  No brain metastases that are untreated, symptomatic, or require steroids to control
             symptoms; or any radiation, surgery, or other therapy to control symptoms from brain
             metastases within 2 months prior to the first study treatment.

          -  No prior chemotherapy for metastatic disease is allowed

          -  No prior treatment with pertuzumab is allowed

          -  No history of exposure to the following cumulative doses of anthracyclines:

          -  Doxorubicin or liposomal doxorubicin &gt; 360 mg/m2

          -  Epirubicin &gt; 720 mg/m2

          -  Mitoxantrone &gt; 120 mg/m2

          -  Idarubicin &gt; 90 mg/m2

          -  If another anthracycline or more than 1 anthracycline has been used, then the
             cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.

          -  No history of palliative radiotherapy within 14 days of randomization

          -  No history of other malignancy within the last 5 years, except for carcinoma in situ
             of the cervix or basal cell or spinocellular carcinoma of the skin

          -  No current uncontrolled hypertension (persistent systolic &gt; 180 mmHg and/or diastolic
             &gt; 100 mmHg)

          -  No LVEF below 50%

          -  No history of significant cardiac disease defined as:

          -  Symptomatic CHF (NYHA classes II-IV)

          -  High-risk uncontrolled arrhythmias

          -  History of myocardial infarction within 6 months prior to randomization

          -  Clinically significant valvular heart disease

          -  No angina pectoris requiring anti-angina treatment

          -  No peripheral neuropathy of Grade ≥ 3 per NCI CTCAE version 4.0.

          -  No current severe, uncontrolled systemic disease (e.g., clinically significant
             cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or
             bone fractures, known infection with HIV, active hepatitis B and/or hepatitis C virus)

          -  No major surgical procedure or significant traumatic injury within 28 days prior to
             randomization or anticipation of the need for major surgery during the course of study
             treatment

          -  No history of receiving any investigational treatment within 28 days of randomization

          -  No history of intolerance (including Grade 3-4 infusion reaction) to trastuzumab

          -  No unwillingness or inability to comply with the requirements of the protocol as
             assessed by the investigator

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before registration in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Wildiers, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UZ Leuven, Leuven, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital De Jolimont</name>
      <address>
        <city>Haine St Paul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge Kortrijk</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique et Maternité Sainte Elisabeth</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Damiaan</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois-Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Rene Huguenin - Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo Di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS - Ospedale Busonera</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VieCuri - Medisch Centrum voor Noord-Limburg - Locatie Venlo</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie Memorial Cancer Centre</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Champalimaud Cancer Center</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E.</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuet</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryhov County Hospital</name>
      <address>
        <city>Jonkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital - Akademiska Sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vastmanland Centralsjukhuset Vasteras</name>
      <address>
        <city>Vasteras</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre NHS Trust - Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian - Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peterborough and Stamford Hospitals NHS Foundation Trust - Peterborough City Hospita</name>
      <address>
        <city>Peterboroug</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton NHS Foundation Trust - Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2012</study_first_submitted>
  <study_first_submitted_qc>May 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2012</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Ado-trastuzumab emtansine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

